Brind.

CorMedix and Mundipharma are collaborating on a product pipeline for REZZAYO filing, with pricing tied to post-TDAPA reimbursement.

4 reports, 3 independent Updated 00:00
Still developing
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

CorMedix and Mundipharma are collaborating on a product pipeline for REZZAYO filing, with pricing tied to post-TDAPA reimbursement.

Who's involved

What this event is mainly about
FDAMedicareMundipharma

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA accepted the sNDA for REZZAYO, and CorMedix is acquiring Heron's assets.1 source
  2. CorMedix and Mundipharma are seeking potential action on product applications, linking pricing to reimbursement.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story